Dec 22, 2021 / 01:30PM GMT
Operator
Greetings, and welcome to the DURECT Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to Mike Arenberg, Chief Financial Officer. Thank you. You may begin.
Michael H. Arenberg - DURECT Corporation - CFO & Secretary
Good morning, and welcome to our call to discuss our license agreement with Innocoll Pharmaceuticals. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.
Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials, our projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10
DURECT Corp To Discuss Agreement Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot